Who Paid My Doc
Milton Hom
Optometrist, Corneal and Contact Management Azusa, CA Doctor of Optometry
NPI 1326158478 CMS profile 15324
822 E Alosta Ave, Azusa, CA 91702
General payments
$762,340
Research payments
$567,365
Ownership & investment interest
$0
Research they led as principal investigator
$236,383
Through program year 2025, Milton Hom of Azusa, CA is reported in the CMS Open Payments database as having received $762,340 across 499 general payments and $567,365 in research payments paid to them. Separately, studies naming them as principal investigator received $236,383 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Optometrist, Corneal and Contact Management profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $36,373 | 60 | |
| 2024 | General | $9,119 | 49 | |
| 2024 | Research | $22,342 | 1 | |
| 2023 | General | $347,209 | 59 | |
| 2023 | Research | $135,651 | 5 | |
| 2022 | General | $93,245 | 95 | |
| 2021 | General | $84,744 | 66 | |
| 2021 | Research | $38,636 | 9 | |
| 2020 | General | $37,196 | 67 | |
| 2020 | Research | $36,935 | 7 | |
| 2019 | General | $154,455 | 103 | |
| 2019 | Research | $333,801 | 12 |
Beside peers
- Milton Hom
- Optometrist, Corneal and Contact Management median
- Middle half of Optometrist, Corneal and Contact Management
- National median
In program year 2025, general payments to Milton Hom were reported at $36,373. Among 618 Optometrist, Corneal and Contact Management profiles paid that year, the median was $227 and the middle half received between $95 and $604.
Show as a table
| Year | Milton Hom | Optometrist, Corneal and Contact Management median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $154,455 | $203 | $84–$530 | $163 |
| 2020 | $37,196 | $88 | $35–$234 | $114 |
| 2021 | $84,744 | $143 | $54–$353 | $132 |
| 2022 | $93,245 | $167 | $65–$422 | $149 |
| 2023 | $347,209 | $195 | $76–$549 | $160 |
| 2024 | $9,119 | $202 | $85–$523 | $164 |
| 2025 | $36,373 | $227 | $95–$604 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
152
Drug cost
$20,419
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cyclosporine | Generic | 31 | $13,288 | |
| Epinastine Hcl | Generic | 66 | $6,179 | |
| Latanoprost | Generic | 40 | $505 | |
| Azelastine Hcl | Generic | 15 | $446 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 9 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Cequa |
|
$192 | — | — |
| LOTEMAX SM |
|
$60 | — | — |
| LUMIGAN |
|
$57 | — | — |
| IYUZEH |
|
$51 | — | — |
| EYSUVIS |
|
$32 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 9 in the dashboard with a free accountRecords
533 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Optometrist, Corneal and Contact Management in California
Kambiz Silani
Optometrist, Corneal and Contact Management · Beverly Hills, CA
Gloria Chiu
Optometrist, Corneal and Contact Management · Los Angeles, CA
John Gelles
Optometrist, Corneal and Contact Management · Sunnyvale, CA
Nathan Schramm
Optometrist, Corneal and Contact Management · Costa Mesa, CA
Jasdeep Soni
Optometrist, Corneal and Contact Management · Bakersfield, CA
Arti Shah
Optometrist, Corneal and Contact Management · Cerritos, CA
Related records
Optometrist, Corneal and Contact Management in California
Practitioners in the same specialty and state, ranked by reported value.
All Optometrist, Corneal and Contact Management
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.